Effect of esmolol on myocardial protection in pediatrics congenital heart defects

Fazelifar, Saeed; Bigdelian, Hamid

Effect of esmolol on myocardial protection in pediatrics congenital heart defects

Authors

Department of Cardiology, Section of Cardiac Surgery, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Although it is accepted that inducing cardioplegia is the gold standard in myocardial protection, there is still no consensus on the exact type of the cardioplegia. There are fewer studies on the type of the cardioplegia in hearts of the children than adults and they are contradictory. The effects of esmolol have been reviewed (a type of ultrashort-acting beta-adrenergic antagonist, i.e., ß-blockers) in conjunction with the cardioplegia due to the effect of the β-blockers in reducing the myocardial ischemia and reperfusion.
Materials and Methods: The left ventricle ejection fraction (LVEF), systolic blood pressure, central venous pressure (CVP), heart rate, etc., were recorded separately in patients who received the cardioplegia without esmolol (n = 35) and with esmolol (n = 30) and matched for the age and sex.
Results: The amount of inotrope used in the group without esmolol (100%) was considerably higher than in the group with esmolol (86.7%). Postoperative arrhythmias did not differ significantly between the two groups. There was no significant difference in the duration of cardiopulmonary bypass (CPB), time of the extubation, length of the ICU stay, the first day EF after surgery, and the first week EF after surgery as well. Creatinine kinase-MB (CKMB) was significantly higher in the group without esmolol during operation than in the group with esmolol.
Conclusions: The patients who received cardioplegia along with esmolol had less inotropic requirement after operation, and increase in EF and cardiac output (CO) 1 week after surgery. In addition, it reduced damage to the heart during surgery, and patients may have greater stability in the cardiac conduction system.

Keywords

References

1.	Preusse CJ, Gebhard MM, Bretschneider HJ. Myocardial "equilibration processes" and myocardial energy turnover during initiation of artificial cardiac arrest with cardioplegi solution -reasons for a sufficiently long cardioplegic perfusion. Thorac Cardiovasc Surg 1981;29:71-6.
2.	Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg 1980;28:295-302.
3.	Hearse DJ, O'Brien K, Braimbridge MV. Protection of the myocardium during ischemic arrest: Dose-response curves for procaine and lignocaine in cardioplegic solutions. J Thorac Cardiovasc Surg. 1981;81:873-9.
4.	Bull C, Cooper J, Stark J. Cardioplegic protection of the child's heart. J Thorac Cardiovasc Surg 1984;88:287-93.
5.	Doenst T, Schlensak C, Beyersdorf F. Cardioplegia in pediatric cardiac surgery: Do we believe in magic? Ann Thorac Surg 2003;75:1668-77.
6.	Young JN, Choy IO, Silva NK, Obayashi DY, Barkan HE. Antegrade cold blood cardioplegia is not demonstrably advantageous over cold crystalloid cardioplegia in surgery for congenital heart disease. J Thorac Cardiovasc Surg 1997;114:1002-9.
7.	Julia P, Young HH, Buckberg GD, Kofsky ER, Bugyi HI. Studies of myocardial protection in the immature heart. IV. Improved tolerance of immature myocardium to hypoxia and ischemia by intravenous metabolic support. J Thorac Cardiovasc Surg 1991;101:23-32.
8.	Magee PG, Gardner TJ, Flaherty JT, Bulkley BH, Goldman RA, Gott VL. Improved myocardial protection with propranolol during induced ischemia. Circulation 1980;62:I49-56.
9.	Manning AS, Keogh JM, Coltart DJ, Hearse DJ. The effect of beta blockade and partial agonist activity during myocardial ischemia. Adv Myocardiol 1983;4:513-20.
10.	Khandoudi N, Percevault-Albadine J, Bril A. Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol 1998;32:443-51.
11.	Lu HR, Vandeplassche G, Wouters L, Flameng W, Borgers M. Effects of beta-adrenoceptor antagonists on cardiac function in ischemic-reperfused myocardium of the isolated working rabbit heart. Eur J Pharmacol 1990;184:65-74.
12.	Kloner RA, Kirshenbaum J, Lange R, Antman EM, Braunwald E. Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia. Am J Cardiol 1985;56:40F-8F.
13.	Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Invest 1980;65:338-46.
14.	Opie LH, Owen P, Thomas M, Samson R. Coronary sinus lactate measurements in assessment of myocardial ischemia. Comparison with changes in lactate-pyruvate and beta-hydroxybutyrate-acetoacetate ratios and with release of hydrogen, phosphate and potassium ions from the heart. Am J Cardiol 1973;32:295-305.
15.	Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation 1975;52:6-15.
16.	Liu XK, Engelman RM, Agrawal HR, Das DK. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: A novel mechanism of action of beta-blockers. J Mol Cell Cardiol 1991;23:1091-100.
17.	Cork RC, Kramer TH, Dreischmeier B, Behr S, DiNardo JA. The effect of esmolol given during cardiopulmonary bypass. Anesth Analg 1995;80:28-40.
18.	Bessho R, Chambers DJ. Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat. J Thorac Cardiovasc Surg 2002;124:340-51.
19.	Borowski A, Raji MR, Eichstaedt HC, Schickendantz S, Korb H. Myocardial protection by pressure- and volume-controlled continuous hypothermic coronary perfusion in combination with Esmolol and nitroglycerine for correction of congenital heart defects in pediatric risk patients. Eur J Cardiothorac Surg 1998;14:243-9.

Advanced Biomedical Research